Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Prof. Dr. Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Cairo University | Egypt

Prof. Dr. Rabab Abdel Moneim is a distinguished authority in Clinical Oncology at the Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. With an extensive career dedicated to cancer research, radiotherapy, and clinical practice, she has made a profound impact on oncology education, treatment innovation, and patient care across the Middle East. Her academic foundation was established at the renowned Kasr El Aini Faculty of Medicine, where she completed her M.B.B.Ch. degree with honors, followed by a master’s degree in Medical Oncology and Radiotherapy, earning the highest distinction across all Cairo universities. She later attained her Doctorate in Oncology, cementing her status as a leading scholar and clinician in the field.Prof. Abdel Moneim has accumulated rich professional experience through her long-standing affiliation with the Kasr El Aini Faculty of Medicine, where she has served in multiple academic and clinical capacities, advancing from house officer and resident to assistant lecturer, assistant professor, and eventually full professor. Her clinical expertise is reflected in her consultancy roles at the New Kasr El-Eini Teaching Hospital and the IMC Hospital Radiotherapy Center. Her early professional journey includes collaboration with Prof. Dr. Hamdy Abd El Azim at the Cairo Cure Center, a partnership that shaped her clinical vision and deepened her specialization in oncology and radiotherapy.Her professional experience extends beyond Egypt, having served as a consultant at King Fahd Hospital in Madina, Saudi Arabia, and maintaining an active registration with the Saudi Commission for Health Specialties in Oncology Medicine. Prof. Abdel Moneim’s commitment to global oncology advancement is further demonstrated through her participation in numerous international conferences and workshops, including ESMO, ESTRO, ASCO, and other major oncology congresses. Her contributions to evidence-based cancer therapy, radiotherapy techniques, and the facilitation of clinical trials across the MENA region have significantly influenced modern oncology practices.An active member of multiple professional societies such as ESTRO, ESMO, the Sarcoma Group, and the Neuro-Oncology Group at Cairo University, Prof. Abdel Moneim continues to contribute to academic excellence and clinical innovation. Her expertise in 3D conformal radiation therapy, stereotactic techniques, IMRT, and RapidArc has set a high standard in radiotherapy advancements. As a dedicated educator, she remains involved in postgraduate teaching and training programs, nurturing the next generation of oncologists.

Profile: Google Scholar

Featured Publications

Abdel Moneim, A. A. R., & El Deeb, M. (2017). Gingival pigmentation: Cause, treatment, and histological preview. Future Dental Journal.

Rady, D., Mubarak, R., & Abdel Moneim, R. A. (2018). Healing capacity of bone marrow mesenchymal stem cells versus platelet-rich fibrin in tibial bone defects of albino rats: An in vivo study. F1000Research.

Abdel Moneim, R. A., El Deeb, M., & Adel, F. (2018). Evaluation of the therapeutic potential of Tamarind seeds (aqueous extract) versus antidiabetic drugs on the histological structure of lingual papillae in diabetic rats. Egyptian Dental Journal, 64(3), Oral Medicine, X-Ray, Oral Biology Section.

Hakam, H. M., Abdel Moneim, R. A., & El Deeb, M. F. (2020). Osteoinductive potential and bone healing capacity of nanocrystalline hydroxyapatite (nHA) versus Biodentine of surgically created defects in rabbits’ alveolar process (an experimental study). Egyptian Journal of Histology.

Abdel Moneim, R. A., Mostafa, A., & Abbass, M. M. S. (2020). In treating glucocorticoid-induced osteoporosis in temporomandibular joint of albino rats; which are more effective: Microvesicles or mesenchymal stem cells? Egyptian Journal of Histology.

El Deeb, M., & Abdel Moneim, R. A. (2018). Remineralization potential of lactose-free and plant-based milk on enamel surface of human teeth subjected to energy drinks. Egyptian Dental Journal, 64(4), Oral Medicine, X-Ray, Oral Biology Section.

Ragaei, A., & Abdel Moneim, R. A. A. (2017). Gingival overgrowth: Drug-induced versus hereditary and idiopathic. Cosmetology & Oro Facial Surgery.

Maria Garrido | Personalized Medicine | Women Researcher Award

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma

Edwin Posadas | Precision Medicine | Best Researcher Award

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. 📚🔬✨

Publication Profile

orcid

Education

Dr. Edwin Posadas 🎓 began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) 🏥. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. 🔬💙

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) 🏥, Association of Philippine Physicians of America (1998) 🇵🇭, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) 🎖️. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) 🔬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) 🚀 and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine 🏥, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 🧬🎗️. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. 🔬💙

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer 🔬, metastasis 🧬, and nanotechnology-based diagnostics 🏥. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. 🎗️

Publication Top Notes